ReviewHematological oncology2022
Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.
Review in Hematological oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?EMBO molecular medicine · 2026Review
- Bivalent aptamer assemblies: A versatile toolkit for precision targeting of B-cell malignancies.Molecular therapy. Nucleic acids · 2026Article
- The biochemical function of bivalent aptamer assemblies against B cell markers CD19 and CD20.Molecular therapy. Nucleic acids · 2025Article
- Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.ACS omega · 2025Review
- Development and Preclinical Evaluation of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Living Medicines Engineered to Fight: A Comprehensive Review on CAR T-Cell Therapy.International journal of hematology-oncology and stem cell research · 2025Review
- Clinical Impact of CD19 Expression Assessed by Quantitative PCR in Lymphoma Patients Undergoing CAR-T Therapy.EJHaem · 2025Article
- Real-world use of tafasitamab preceding CD19-directed chimeric antigen receptor T-cell therapy for relapsed or refractory diffuse large B-cell lymphoma.Biomarker research · 2025Article
- Targeted therapies and resistance mechanisms in lymphoma: Current landscape and emerging solutions.Oncoscience · 2025Review
- Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.International journal of molecular sciences · 2024Review
- Targeting CD19-positive lymphomas with the antibodydrug conjugate loncastuximab tesirine: preclinical evidence of activity as a single agent and in combination therapy.Haematologica · 2024Article
- CD19/CD20 dual-targeted chimeric antigen receptor-engineered natural killer cells exhibit improved cytotoxicity against acute lymphoblastic leukemia.Journal of translational medicine · 2024Article
- CAR-T Cell Therapy in the Treatment of Pediatric Non-Hodgkin Lymphoma.Journal of personalized medicine · 2023Review
- Review
- Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy.Cancers · 2023Article
- Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper.Hematological oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Selection of the most appropriate treatment strategy should be based on individual patient characteristics and the goal of therapy. However, evidence and knowledge about the sequencing of anti-CD19 therapies are limited. Here, we review the current evidence for CD19 as a target in diffuse large B-cell lymphoma and consider approaches to the use of anti-CD19 therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.